digital health startups weight loss glp-1 Virtual startups: Pill mills or the future of obesity care? Beyond the Hype: Where and

Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

In January 2025, Novo Nordisk stated that the United States Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease progression, kidney failure (end-stage renal disease), and cardiovascular disease-related death in individuals with type 2 diabetes and chronic kidney disease (CKD)

EMBO Mol Med 8(6):595608

[ 9 , 10 ] By stabilizing the production of certain hormones like serotonin, BPC 157 may promote mental health by improving depression-type symptoms

PLoS One 9:e100778